NASH Treatment & Endpoints | Room 717

Saturday, June 16, 2018
2:00 PM to 3:45 PM

Chairs: Zobair Younossi & Scott Friedman

Invited Presentations:

2:00pm
Pathogenesis of NAFLD
Ariel Feldstein, University Of California San Diego, La Jolla

2:25pm
Current assessment and management of NASH
Zobair Younossi, Inova Fairfax Medical Campus, Washington

2:50pm
NASH Trial Endpoints and Emerging therapies
Kris Kowdley, Swedish Medical Center, Seattle Oral Abstracts:

3:15pm
Predictors of de novo Non-alcoholic Fatty Liver Disease (NAFLD) post-Liver Transplantation and Associated Fibrosis
Zita Galvin, University of Toronto, Toronto

Oral Abstracts:

3:30pm
Histologic Predictors of Liver-Related Outcomes and Mortality in Patients with Chronic hepatitis B and Non-Alcoholic Fatty Liver Disease
Hannah Choi, University Health Network, Toronto

Return to Schedule